A loop ileostomy is the appropriate procedure for defunctioning the colon to protect an anastomosis. This involves taking a loop of ileum, making a horizontal incision, and bringing it up to the skin. It is commonly used after rectal cancer surgery and can be reversed at a later time.

An end colostomy is performed when an anastomosis is not possible or desirable, and the colon needs to be diverted or resected. The distal part of the colon is brought up to the skin in this procedure.

An end ileostomy is typically done after the complete removal of the colon or when an ileocolic anastomosis is not planned. While it can be used to defunction the colon, it is more challenging to reverse.

A gastrostomy is used for gastric decompression or feeding.

A loop jejunostomy is used as a high-output stoma and may be performed after an emergency laparotomy with planned early closure.

Abdominal stomas are created during various abdominal procedures to bring the lumen or contents of organs onto the skin. Typically, this involves the bowel, but other organs may also be diverted if necessary. The type and method of construction of the stoma will depend on the contents of the bowel. Small bowel stomas should be spouted to prevent irritant contents from coming into contact with the skin, while colonic stomas do not require spouting. Proper siting of the stoma is crucial to reduce the risk of leakage and subsequent maceration of the surrounding skin. The type and location of the stoma will vary depending on the purpose, such as defunctioning the colon or providing feeding access. Overall, abdominal stomas are a necessary medical intervention that requires careful consideration and planning.

Acromegaly: Excess Growth Hormone and its Features

Acromegaly is a condition characterized by excess growth hormone, which is usually caused by a pituitary adenoma in over 95% of cases. However, a minority of cases are caused by ectopic GHRH or GH production by tumours such as pancreatic. The condition is associated with several features, including a coarse facial appearance, spade-like hands, and an increase in shoe size. Patients may also have a large tongue, prognathism, and interdental spaces. Excessive sweating and oily skin are also common, caused by sweat gland hypertrophy.

In addition to these physical features, patients with acromegaly may also experience symptoms of a pituitary tumour, such as hypopituitarism, headaches, and bitemporal hemianopia. Raised prolactin levels are also seen in about one-third of cases, which can lead to galactorrhoea. It is important to note that 6% of patients with acromegaly have MEN-1, a genetic disorder that affects multiple endocrine glands.

Complications of acromegaly include hypertension, diabetes (seen in over 10% of cases), cardiomyopathy, and an increased risk of colorectal cancer. Early diagnosis and treatment of acromegaly are crucial to prevent these complications and improve patient outcomes.

Comparing Medications for Trigeminal Neuralgia Treatment

Trigeminal neuralgia is a condition characterized by severe facial pain that occurs in one or more branches of the trigeminal nerve. To treat this condition, anticonvulsant medications are often prescribed. Here, we compare five commonly used medications for trigeminal neuralgia treatment.

Carbamazepine is the recommended first-line treatment for trigeminal neuralgia by the National Institute for Health and Care Excellence (NICE). Topiramate is not typically used for trigeminal neuralgia, as it is primarily indicated for migraine prophylaxis. Amitriptyline is recommended for neuropathic pain, but not specifically for trigeminal neuralgia. Duloxetine is also indicated for neuropathic pain, but not for trigeminal neuralgia. Gabapentin is recommended for neuropathic pain, but not for trigeminal neuralgia, as carbamazepine is the preferred first-line treatment for this condition.

In summary, carbamazepine is the recommended first-line treatment for trigeminal neuralgia, while the other medications mentioned may be more appropriate for other conditions.

Differentiating Chronic Rhinosinusitis from Other Headache Disorders

Chronic rhinosinusitis is a condition characterized by inflammation of the paranasal sinuses and nasal passages that lasts for 12 weeks or longer. Patients with chronic rhinosinusitis typically present with symptoms such as nasal congestion, coughing, persistent headache that worsens on bending forwards, facial pain, nasal discharge, and postnasal drip. Predisposing factors for chronic rhinosinusitis include atopy, nasal obstruction, recent local infection, swimming or diving, and smoking. Management of chronic rhinosinusitis involves avoidance of allergens, intranasal corticosteroids, and nasal irrigation with saline.

Acute sinusitis shares many features with chronic rhinosinusitis, but the history of symptoms is much shorter. Treatment for acute sinusitis includes analgesia, intranasal decongestants or nasal saline, and intranasal corticosteroids if symptoms persist for more than ten days. Oral antibiotics may be given for severe presentations.

Cluster headaches are characterized by intense, sharp, stabbing pain around one eye, accompanied by eye redness, lacrimation, lid swelling, nasal stuffiness, skin erythema, miosis or ptosis. Cluster headaches occur in clusters lasting between four and 12 weeks, with patients feeling completely fine in between clusters. Tension headaches are described as a band-like headache that does not impair activities of daily living.

Postnasal drip (PND) typically presents with a chronic cough and bad breath, unlike the presentation in chronic rhinosinusitis. It is important to differentiate chronic rhinosinusitis from other headache disorders to ensure appropriate management and treatment.

Kawasaki disease can lead to coronary artery aneurysms, which can be detected through an echocardiogram. To diagnose Kawasaki disease, the patient must have a fever for more than 5 days and at least 4 of the following symptoms: bilateral conjunctivitis, cervical lymphadenopathy, polymorphic rash, cracked lips/strawberry tongue, and oedema/desquamation of the hands/feet. This patient has a rash, conjunctivitis, mucosal involvement, and desquamation of the hands and feet, indicating Kawasaki disease. While cardiac magnetic resonance angiography is a non-invasive alternative to coronary angiography, it is not first-line due to its cost and limited availability. A chest x-ray may be considered to check for cardiomegaly, but it is not necessary as echocardiography can diagnose pericarditis or myocarditis without radiation. Coronary angiography is invasive and carries risks, so it is not first-line unless large coronary artery aneurysms are seen on echocardiography. A lumbar puncture is not necessary at this stage unless the patient displays symptoms of meningitis.

Understanding Kawasaki Disease

Kawasaki disease is a rare type of vasculitis that primarily affects children. It is important to identify this disease early on as it can lead to serious complications, such as coronary artery aneurysms. The disease is characterized by a high-grade fever that lasts for more than five days and is resistant to antipyretics. Other symptoms include conjunctival injection, bright red, cracked lips, strawberry tongue, cervical lymphadenopathy, and red palms and soles that later peel.

Diagnosis of Kawasaki disease is based on clinical presentation as there is no specific diagnostic test available. Management of the disease involves high-dose aspirin, which is one of the few indications for aspirin use in children. Intravenous immunoglobulin is also used as a treatment option. Echocardiogram is the initial screening test for coronary artery aneurysms, rather than angiography.

Complications of Kawasaki disease can be serious, with coronary artery aneurysm being the most common. It is important to recognize the symptoms of Kawasaki disease early on and seek medical attention promptly to prevent potential complications.

The recommended first-line antibiotic for patients with confirmed Clostridium difficile infection is oral vancomycin. This infection typically occurs in patients who have recently taken broad-spectrum antibiotics, such as co-amoxiclav and ciprofloxacin, which disrupt the gut flora. Discontinuing the implicated antibiotic and starting appropriate eradicative therapy is necessary. Oral fidaxomicin is an alternative but is less available. Metronidazole is no longer a first-line antibiotic due to lower cure rates than vancomycin, but it may be used if vancomycin is not available. IV vancomycin is ineffective as insufficient quantities are excreted into the gut lumen. Clindamycin is not a cure for Clostridium difficile but is associated with an increased risk of developing it. Conservative management is not recommended as the infection may worsen and lead to complications such as toxic megacolon.

Clostridioides difficile is a type of bacteria that is commonly found in hospitals. It is a Gram positive rod that produces an exotoxin which can cause damage to the intestines, leading to a condition called pseudomembranous colitis. This bacteria usually develops when the normal gut flora is suppressed by broad-spectrum antibiotics, with second and third generation cephalosporins being the leading cause of C. difficile. Other risk factors include proton pump inhibitors. Symptoms of C. difficile include diarrhea, abdominal pain, and a raised white blood cell count. The severity of the infection can be determined using the Public Health England severity scale, which ranges from mild to life-threatening.

To diagnose C. difficile, a stool sample is tested for the presence of C. difficile toxin (CDT). Treatment for a first episode of C. difficile infection typically involves oral vancomycin for 10 days, with fidaxomicin or a combination of oral vancomycin and IV metronidazole being used as second and third-line therapies. Recurrent infections occur in around 20% of patients, increasing to 50% after their second episode. In such cases, oral fidaxomicin is recommended within 12 weeks of symptom resolution, while oral vancomycin or fidaxomicin can be used after 12 weeks. For life-threatening C. difficile infections, oral vancomycin and IV metronidazole are used, and surgery may be considered with specialist advice. Other therapies, such as bezlotoxumab and fecal microbiota transplant, may also be considered for preventing recurrences in certain cases.

Fluoxetine is the preferred SSRI for children and adolescents.

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as the first-line treatment for depression. Citalopram and fluoxetine are the preferred SSRIs, while sertraline is recommended for patients who have had a myocardial infarction. However, caution should be exercised when prescribing SSRIs to children and adolescents. Gastrointestinal symptoms are the most common side-effect, and patients taking SSRIs are at an increased risk of gastrointestinal bleeding. Patients should also be aware of the possibility of increased anxiety and agitation after starting a SSRI. Fluoxetine and paroxetine have a higher propensity for drug interactions.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning regarding the use of citalopram due to its association with dose-dependent QT interval prolongation. As a result, citalopram and escitalopram should not be used in patients with congenital long QT syndrome, known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. The maximum daily dose of citalopram is now 40 mg for adults, 20 mg for patients older than 65 years, and 20 mg for those with hepatic impairment.

When initiating antidepressant therapy, patients should be reviewed by a doctor after 2 weeks. Patients under the age of 25 years or at an increased risk of suicide should be reviewed after 1 week. If a patient responds well to antidepressant therapy, they should continue treatment for at least 6 months after remission to reduce the risk of relapse. When stopping a SSRI, the dose should be gradually reduced over a 4 week period, except for fluoxetine. Paroxetine has a higher incidence of discontinuation symptoms, including mood changes, restlessness, difficulty sleeping, unsteadiness, sweating, gastrointestinal symptoms, and paraesthesia.

When considering the use of SSRIs during pregnancy, the benefits and risks should be weighed. Use during the first trimester may increase the risk of congenital heart defects, while use during the third trimester can result in persistent pulmonary hypertension of the newborn. Paroxetine has an increased risk of congenital malformations, particularly in the first trimester.

Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

For a patient with poorly controlled moderate hypertension who is already taking an ACE inhibitor, calcium channel blocker, and thiazide diuretic, the recommended next step would be to add spironolactone if their potassium level is less than 4.5mmol/L. Atenolol may be considered as a fourth-line agent if the potassium level is over 4.5mmol/L, but spironolactone is preferred according to NICE guidelines. Hydralazine should not be used outside of specialist care, and indapamide is not the best option as the patient is already taking a thiazide diuretic. Prazosin is an alternative to spironolactone, but spironolactone is preferred given the lower potassium level.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Bacterial vaginosis (BV) is a common vaginal infection that affects many women, with up to 50% of cases being asymptomatic. The main symptom of BV is a fishy-smelling discharge from the vagina.

In pregnant women, BV can lead to late miscarriage and preterm delivery if left untreated. Therefore, all pregnant women who experience symptoms should receive treatment. This typically involves taking oral metronidazole twice a day for 5-7 days, as a single 2-gram dose is not recommended during pregnancy.

However, for asymptomatic pregnant women with BV, treatment is considered on a case-by-case basis. This is because research suggests that identifying and treating asymptomatic cases does not necessarily reduce the risk of preterm birth. This information is based on guidelines from NICE CKS.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimes. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.